{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:14:21Z","timestamp":1793164461217,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PH1\/105"],"award-info":[{"award-number":["PH1\/105"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00262-017-2034-7","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T05:29:54Z","timestamp":1498627794000},"page":"1425-1436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":365,"title":["The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity"],"prefix":"10.1007","volume":"66","author":[{"given":"Fiona C.","family":"Thistlethwaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gilham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic G.","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Byatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kirillova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Chester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel B.","family":"Westwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E. R.","family":"Halford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Nabarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"2034_CR1","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38","journal-title":"Sci Transl Med"},{"key":"2034_CR2","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25","journal-title":"Sci Transl Med"},{"key":"2034_CR3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540\u2013549","journal-title":"J Clin Oncol"},{"key":"2034_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528","journal-title":"Lancet"},{"key":"2034_CR5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517","journal-title":"N Engl J Med"},{"key":"2034_CR6","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139","journal-title":"Sci Transl Med"},{"key":"2034_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"67","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165\u2013183","journal-title":"Annu Rev Med"},{"key":"2034_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62\u201368","journal-title":"Science"},{"key":"2034_CR9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.seminoncol.2015.05.005","volume":"42","author":"SA Feldman","year":"2015","unstructured":"Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA (2015) Adoptive cell therapy\u2013tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin Oncol 42:626\u2013639","journal-title":"Semin Oncol"},{"key":"2034_CR10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.2014.60.3449","volume":"33","author":"KJ Curran","year":"2015","unstructured":"Curran KJ, Brentjens RJ (2015) Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol 33:1703\u20131706","journal-title":"J Clin Oncol"},{"key":"2034_CR11","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106\u20136115","journal-title":"Clin Cancer Res"},{"key":"2034_CR12","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20\u2013e22","journal-title":"J Clin Oncol"},{"key":"2034_CR13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","volume":"117","author":"CH Lamers","year":"2011","unstructured":"Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J et al (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117:72\u201382","journal-title":"Blood"},{"key":"2034_CR14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264\u20131270","journal-title":"Nat Med"},{"key":"2034_CR15","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2002.08.017","volume":"20","author":"NL Berinstein","year":"2002","unstructured":"Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197\u20132207","journal-title":"J Clin Oncol"},{"key":"2034_CR16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nm0996-979","volume":"2","author":"RH Begent","year":"1996","unstructured":"Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP et al (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2:979\u2013984","journal-title":"Nat Med"},{"key":"2034_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1155\/2000\/672706","volume":"16","author":"KA Chester","year":"2000","unstructured":"Chester KA, Bhatia J, Boxer G, Cooke SP, Flynn AA, Huhalov A et al (2000) Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Mark 16:53\u201362","journal-title":"Dis Mark"},{"key":"2034_CR18","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1158\/1078-0432.CCR-06-0769","volume":"12","author":"A Mayer","year":"2006","unstructured":"Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J et al (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12:6509\u20136516","journal-title":"Clin Cancer Res"},{"key":"2034_CR19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00002371-200203000-00002","volume":"25","author":"DE Gilham","year":"2002","unstructured":"Gilham DE, O\u2019Neil A, Hughes C, Guest RD, Kirillova N, Lehane M et al (2002) Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 25:139\u2013151","journal-title":"J Immunother"},{"key":"2034_CR20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O\u2019Neill A et al (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28:203\u2013211","journal-title":"J Immunother"},{"key":"2034_CR21","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.178.7.4650","volume":"178","author":"AA Hombach","year":"2007","unstructured":"Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE, Abken H (2007) T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 178:4650\u20134657","journal-title":"J Immunol"},{"key":"2034_CR22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10350-004-6659-1","volume":"46","author":"AJ Sheen","year":"2003","unstructured":"Sheen AJ, Irlam J, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE et al (2003) Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum 46:793\u2013804","journal-title":"Dis Colon Rectum"},{"key":"2034_CR23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/sj.bjc.6600857","volume":"88","author":"AJ Sheen","year":"2003","unstructured":"Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE (2003) T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 88:1119\u20131127","journal-title":"Br J Cancer"},{"key":"2034_CR24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","volume":"166","author":"NM Haynes","year":"2001","unstructured":"Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ et al (2001) Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 166:182\u2013187","journal-title":"J Immunol"},{"key":"2034_CR25","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233\u20135239","journal-title":"J Clin Oncol"},{"key":"2034_CR26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415\u2013419","journal-title":"Science"},{"key":"2034_CR27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018\u20131028","journal-title":"N Engl J Med"},{"key":"2034_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-013-1492-9","volume":"63","author":"RD Guest","year":"2014","unstructured":"Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ et al (2014) Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I\/II clinical trial. Cancer Immunol Immunother 63:133\u2013145","journal-title":"Cancer Immunol Immunother"},{"key":"2034_CR29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/42.9.7520463","volume":"42","author":"ZR Shi","year":"1994","unstructured":"Shi ZR, Tacha D, Itzkowitz SH (1994) Monoclonal antibody COL-1 reacts with restricted epitopes on carcinoembryonic antigen: an immunohistochemical study. J Histochem Cytochem 42:1215\u20131219","journal-title":"J Histochem Cytochem"},{"key":"2034_CR30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1479-5876-10-69","volume":"10","author":"RP Somerville","year":"2012","unstructured":"Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME (2012) Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. J Transl Med 10:69","journal-title":"J Transl Med"},{"key":"2034_CR31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/156652310791111001","volume":"10","author":"JS Bridgeman","year":"2010","unstructured":"Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE (2010) Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 10:77\u201390","journal-title":"Curr Gene Ther"},{"key":"2034_CR32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","volume":"22","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff CA, Rosenberg SA, Restifo NP (2016) Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22:26\u201336","journal-title":"Nat Med"},{"key":"2034_CR33","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA\u00a0+\u00a0liver metastases. Clin Cancer Res 21:3149\u20133159","journal-title":"Clin Cancer Res"},{"key":"2034_CR34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PPO.0000000000000034","volume":"20","author":"HJ Pegram","year":"2014","unstructured":"Pegram HJ, Park JH, Brentjens RJ (2014) CD28z CARs and armored CARs. Cancer J 20:127\u2013133","journal-title":"Cancer J"},{"key":"2034_CR35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/1097-0142(19820515)49:10<2077::AID-CNCR2820491020>3.0.CO;2-X","volume":"49","author":"DJ Ahnen","year":"1982","unstructured":"Ahnen DJ, Nakane PK, Brown WR (1982) Ultrastructural localization of carcinoembryonic antigen in normal intestine and colon cancer: abnormal distribution of CEA on the surfaces of colon cancer cells. Cancer 49:2077\u20132090","journal-title":"Cancer"},{"issue":"Pt 2","key":"2034_CR36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1042\/bj3460519","volume":"346","author":"MK Boehm","year":"2000","unstructured":"Boehm MK, Corper AL, Wan T, Sohi MK, Sutton BJ, Thornton JD et al (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 346(Pt 2):519\u2013528","journal-title":"Biochem J"},{"key":"2034_CR37","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/ijc.2910520509","volume":"52","author":"J Kim","year":"1992","unstructured":"Kim J, Kaye FJ, Henslee JG, Shively JE, Park JG, Lai SL et al (1992) Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer 52:718\u2013725","journal-title":"Int J Cancer"},{"key":"2034_CR38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1465-9921-14-85","volume":"14","author":"E Klaile","year":"2013","unstructured":"Klaile E, Klassert TE, Scheffrahn I, Muller MM, Heinrich A, Heyl KA et al (2013) Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respir Res 14:85","journal-title":"Respir Res"},{"key":"2034_CR39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843\u2013851","journal-title":"Mol Ther"},{"key":"2034_CR40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA et al (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19:620\u2013626","journal-title":"Mol Ther"},{"key":"2034_CR41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"L Johnson","year":"2017","unstructured":"Johnson L, June C (2017) Driving gene-engineered T cell immunnotherapy of cancer. Cell Res 27:38\u201358","journal-title":"Cell Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2034-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T08:29:19Z","timestamp":1508228959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2034-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2034"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2034-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}